Is Yield10 Bioscience Stock a Good Investment?
Yield10 Bioscience Investment Advice | YTEN |
- Examine Yield10 Bioscience's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Yield10 Bioscience's leadership team and their track record. Good management can help Yield10 Bioscience navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Yield10 Bioscience's business and its evolving consumer preferences.
- Compare Yield10 Bioscience's performance and market position to its competitors. Analyze how Yield10 Bioscience is positioned in terms of product offerings, innovation, and market share.
- Check if Yield10 Bioscience pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Yield10 Bioscience's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Yield10 Bioscience stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Yield10 Bioscience is a good investment.
Sell | Buy |
Sell
Market Performance | Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Yield10 Bioscience Stock
Researching Yield10 Bioscience's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 18.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 20.14. Yield10 Bioscience last dividend was issued on the 16th of January 2020. The entity had 1:24 split on the 3rd of May 2024.
To determine if Yield10 Bioscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Yield10 Bioscience's research are outlined below:
| Yield10 Bioscience had very high historical volatility over the last 90 days | |
| Yield10 Bioscience has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 60 K. Net Loss for the year was (14.46 M) with loss before overhead, payroll, taxes, and interest of (7.3 M). | |
| Yield10 Bioscience currently holds about 10.16 M in cash with (10.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Yield10 Bioscience has a frail financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company outstanding shares are owned by insiders |
Yield10 Bioscience Quarterly Cost Of Revenue |
|
Yield10 Bioscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Yield10 Bioscience. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Yield10 Bioscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Yield10 Bioscience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Yield10 Bioscience's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-27 | 2023-12-31 | -0.3 | -0.27 | 0.03 | 10 | ||
2015-08-12 | 2015-06-30 | -0.26 | -0.22 | 0.04 | 15 | ||
2023-03-14 | 2022-12-31 | -0.6 | -0.67 | -0.07 | 11 | ||
2021-03-16 | 2020-12-31 | -0.7 | -0.79 | -0.09 | 12 | ||
2023-08-14 | 2023-06-30 | -0.54 | -0.64 | -0.1 | 18 | ||
2021-08-11 | 2021-06-30 | -0.54 | -0.64 | -0.1 | 18 | ||
2023-05-10 | 2023-03-31 | -0.63 | -0.76 | -0.13 | 20 | ||
2021-11-10 | 2021-09-30 | -0.65 | -0.49 | 0.16 | 24 |
Know Yield10 Bioscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Yield10 Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Yield10 Bioscience backward and forwards among themselves. Yield10 Bioscience's institutional investor refers to the entity that pools money to purchase Yield10 Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cutter & Co Brokerage, Inc. | 2024-06-30 | 0.0 | Salem Investment Counselors Inc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Yield10 Bioscience's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 345.46 K.Market Cap |
|
Yield10 Bioscience's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.25) | (4.04) | |
| Return On Capital Employed | 13.54 | 14.22 | |
| Return On Assets | (4.25) | (4.04) | |
| Return On Equity | 5.24 | 5.50 |
Determining Yield10 Bioscience's profitability involves analyzing its financial statements and using various financial metrics to determine if Yield10 Bioscience is a good buy. For example, gross profit margin measures Yield10 Bioscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Yield10 Bioscience's profitability and make more informed investment decisions.
Evaluate Yield10 Bioscience's management efficiency
Yield10 Bioscience has return on total asset (ROA) of (1.7811) % which means that it has lost $1.7811 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.0809) %, meaning that it created substantial loss on money invested by shareholders. Yield10 Bioscience's management efficiency ratios could be used to measure how well Yield10 Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Yield10 Bioscience's Return On Capital Employed is very stable compared to the past year. As of the 7th of January 2025, Return On Equity is likely to grow to 5.50, though Return On Tangible Assets are likely to grow to (4.04). At this time, Yield10 Bioscience's Non Current Assets Total are very stable compared to the past year. As of the 7th of January 2025, Non Currrent Assets Other is likely to grow to about 388.3 K, while Total Assets are likely to drop about 3.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (6.75) | (7.09) | |
| Tangible Book Value Per Share | (6.75) | (7.09) | |
| Enterprise Value Over EBITDA | (0.26) | (0.27) | |
| Price Book Value Ratio | (0.88) | (0.84) | |
| Enterprise Value Multiple | (0.26) | (0.27) | |
| Price Fair Value | (0.88) | (0.84) | |
| Enterprise Value | 4.6 M | 4.4 M |
Yield10 Bioscience benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta 1.433 |
Basic technical analysis of Yield10 Stock
As of the 7th of January, Yield10 Bioscience maintains the Mean Deviation of 14.53, downside deviation of 19.6, and Market Risk Adjusted Performance of 0.2542. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Yield10 Bioscience, as well as the relationship between them.Yield10 Bioscience's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Yield10 Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Yield10 Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Yield10 Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yield10 Bioscience's Outstanding Corporate Bonds
Yield10 Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Yield10 Bioscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Yield10 bonds can be classified according to their maturity, which is the date when Yield10 Bioscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Yield10 Bioscience's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Yield10 Bioscience's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0298 | |||
| Market Risk Adjusted Performance | 0.2542 | |||
| Mean Deviation | 14.53 | |||
| Semi Deviation | 16.59 | |||
| Downside Deviation | 19.6 | |||
| Coefficient Of Variation | 4022.93 | |||
| Standard Deviation | 22.46 | |||
| Variance | 504.27 | |||
| Information Ratio | 0.0236 | |||
| Jensen Alpha | 0.5076 | |||
| Total Risk Alpha | 0.0467 | |||
| Sortino Ratio | 0.0271 | |||
| Treynor Ratio | 0.2442 | |||
| Maximum Drawdown | 114.76 | |||
| Value At Risk | (31.37) | |||
| Potential Upside | 40.79 | |||
| Downside Variance | 384.03 | |||
| Semi Variance | 275.14 | |||
| Expected Short fall | (18.99) | |||
| Skewness | 1.42 | |||
| Kurtosis | 3.7 |
| Risk Adjusted Performance | 0.0298 | |||
| Market Risk Adjusted Performance | 0.2542 | |||
| Mean Deviation | 14.53 | |||
| Semi Deviation | 16.59 | |||
| Downside Deviation | 19.6 | |||
| Coefficient Of Variation | 4022.93 | |||
| Standard Deviation | 22.46 | |||
| Variance | 504.27 | |||
| Information Ratio | 0.0236 | |||
| Jensen Alpha | 0.5076 | |||
| Total Risk Alpha | 0.0467 | |||
| Sortino Ratio | 0.0271 | |||
| Treynor Ratio | 0.2442 | |||
| Maximum Drawdown | 114.76 | |||
| Value At Risk | (31.37) | |||
| Potential Upside | 40.79 | |||
| Downside Variance | 384.03 | |||
| Semi Variance | 275.14 | |||
| Expected Short fall | (18.99) | |||
| Skewness | 1.42 | |||
| Kurtosis | 3.7 |
Consider Yield10 Bioscience's intraday indicators
Yield10 Bioscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Yield10 Bioscience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Yield10 Bioscience time-series forecasting models is one of many Yield10 Bioscience's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Yield10 Bioscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Yield10 Stock media impact
Far too much social signal, news, headlines, and media speculation about Yield10 Bioscience that are available to investors today. That information is available publicly through Yield10 media outlets and privately through word of mouth or via Yield10 internal channels. However, regardless of the origin, that massive amount of Yield10 data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Yield10 Bioscience news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Yield10 Bioscience relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Yield10 Bioscience's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Yield10 Bioscience alpha.
Yield10 Bioscience Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Yield10 Bioscience can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Already Invested in Yield10 Bioscience?
The danger of trading Yield10 Bioscience is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Yield10 Bioscience is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Yield10 Bioscience. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Yield10 Bioscience is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Yield10 Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Yield10 Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Yield10 Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Yield10 Bioscience Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Yield10 Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Yield10 Stock, please use our How to Invest in Yield10 Bioscience guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Yield10 Bioscience. If investors know Yield10 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Yield10 Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (20.14) | Revenue Per Share | Quarterly Revenue Growth 4 | Return On Assets | Return On Equity |
The market value of Yield10 Bioscience is measured differently than its book value, which is the value of Yield10 that is recorded on the company's balance sheet. Investors also form their own opinion of Yield10 Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Yield10 Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Yield10 Bioscience's market value can be influenced by many factors that don't directly affect Yield10 Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Yield10 Bioscience's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Yield10 Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Yield10 Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.